Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Robotic Surgery Surgical Procedures Innovation

Johnson & Johnson Unveils Details On Ottava Soft-Tissue Robot, Chasing Intuitive, Medtronic

Executive Summary

J&J said its Ottava robotic platform has six robotic arms, “zero footprint,” and can be used for various procedures.

You may also be interested in...



J&J Pushes Back Launch Of Ottava Robotic Platform By Two Years

The company originally expected the first-in-human trial of the soft-tissue robotic surgery system to begin in late 2022 and reach the market by 2023, but the company now expects those trials to begin in 2024.

J&J Finishes Tough Year With Optimism For 2021

J&J expects its medical device sales to begin growing rapidly by the middle of 2021 as the pandemic subsides.

New Trial Shows BENEFIT Of J&J/Auris’ Monarch Bronchoscopy Platform

New published results demonstrate J&J/Auris’ robotic is safe and effective at diagnosing peripheral pulmonary lesions.

Table

View full table

Related Content

Medtech Insight
Medtech Insight
Medtech Insight

Topics

Related Companies

Tags:
Robotic Surgery Surgical Procedures Innovation
Latest News

Minute Insight: Acutus Adds Another Device To The Left-Heart Business It Sold To Medtronic

How Europe’s Nomenclature System Works And Offers New Insights

MHRA Offers Medtechs Extra Transition Time For UK Regulatory System Compliance

For Second Time This Month, Medtronic Announces Class I FDA Recall Related To HeartWare System Component

UsernamePublicRestriction

Register

MT143115

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By